STAT Reports Experts Agree Kratom and 7-OH Should Be Regulated but Split on How, With Alameda Health System's Andrew Herring Saying 'Make It Illegal,' UNC's Nabarun Dasgupta Praising the DEA's Potency-Threshold Approach, Yale's Katherine Hill Calling Scheduling 'Very Extreme,' and NIDA's Nora Volkow Saying Proper Regulation 'Would Minimize the Harms'

TL;DR

Addiction clinicians, researchers, policy advocates, and the American Kratom Association told STAT they agree concentrated 7-hydroxymitragynine (7-OH) products and kratom need regulation but disagree on whether the answer is the DEA's proposed Schedule I placement of 7-OH above a potency threshold, state licensing and testing regimes like Utah's, or an outright ban, according to a September 30, 2026 report by STAT's Theresa Gaffney. Andrew Herring of Alameda Health System said 'make it illegal,' Nabarun Dasgupta of the University of North Carolina said the threshold approach 'could be really cool,' Yale's Katherine Hill called full scheduling 'very extreme' without a fuller risk-benefit picture, and NIDA director Nora Volkow said proper regulation 'would minimize the harms' while expressing interest in mitragynine as a potential addiction treatment and painkiller. STAT reported the DEA has not finalized its July proposal, that the comment period ended September 10 with nearly 36,000 submissions, and that the agency separately placed three synthetic kratom-related compounds in Schedule I without a threshold caveat.

Addiction clinicians, researchers, and policy advocates told STAT that kratom and concentrated 7-hydroxymitragynine (7-OH) products need regulation but differ on whether the answer is federal scheduling, state licensing, or a ban, according to a September 30, 2026 report by STAT addiction reporter Theresa Gaffney. The piece, headlined "Kratom and 7-OH should be regulated, experts agree. They're split on how," runs through the options on the table: the Drug Enforcement Administration's pending proposal to place 7-OH above a potency threshold in Schedule I, state licensing and testing regimes of the kind Utah and West Virginia have adopted, and outright prohibition.

The DEA's July proposal, as STAT describes it, targets 7-OH "above a certain threshold of potency." The agency's July 1 announcement, as reported at the time, set that threshold at 0.050 percent 7-OH by dry weight for plant material and 1 milligram per unit for finished products, and federal officials described the action as aimed at concentrated and synthetic products, which contain far more 7-OH than the trace amounts in natural leaf, and not at leaf kratom.

Where the federal action stands

STAT reported that the DEA "has not yet finalized the law, but has moved three less common kratom-related synthetics into Schedule I without a threshold caveat." That refers to the August order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I through August 2028. The extended public comment period on the 7-OH threshold "ended on Sept. 10 with nearly 36,000 submissions," according to STAT. Regulations.gov listed 30,346 posted comments as of September 12, and STAT did not explain the difference between the two figures. If finalized, the temporary order could stay in effect for up to two years with a possible one-year extension, STAT reported.

The piece also placed the proposal in the context of state action. STAT reported that Massachusetts issued a temporary statewide ban on all kratom products in late August and that pressure for action "on all types of kratom is mounting" after two University of Mississippi students died this month with kratom products found at both scenes, adding in a parenthetical that authorities have not claimed kratom contributed to either death. STAT's report does not specify whether the products found were concentrated or synthetic 7-OH preparations or natural leaf kratom; Lafayette County investigators have said the same about any confirmed link.

The case for scheduling

The most direct call for prohibition in the piece came from Andrew Herring, chief of addiction medicine at Alameda Health System in Oakland. "Make it illegal," Herring told STAT. "The most dangerous substance there is, is the substance that's marketed as safe but is actually dangerous."

STAT also quoted Marty Makary, who was Food and Drug Administration commissioner when the agency held a press conference on 7-OH in July 2025. Makary said then that the government had "a history of being asleep at the wheel," citing tobacco and OxyContin, and urged action so the country would not be caught flat-footed again, according to STAT.

Nabarun Dasgupta, a pharmacoepidemiologist at the University of North Carolina who STAT identified as a harm reduction advocate, praised the federal design. "I think the federal regulations are great," Dasgupta said of the threshold approach, adding, "This could be really cool." His reasoning, as STAT reported it, was that slowing the pace of new products, legal or illegal, gives people who use drugs time to develop protective habits.

The case against a blanket ban

Katherine Hill, an epidemiology Ph.D. candidate at the Yale School of Public Health, told STAT that scheduling goes too far on the current evidence. "To go all the way to scheduling seems very extreme to me when we haven't fully fleshed out the full risk-benefit profile of these substances," Hill said. "We need more time to figure that out. We need time for clinical trials."

Myles Jen Kin, an addiction clinician in Massachusetts, where STAT reported the state issued its temporary ban in late August, said he is not a fan of 7-OH but that "a blanket ban like this can cause some problems."

Regina LaBelle, an addiction policy professor at Georgetown and a former official in the White House Office of National Drug Control Policy, questioned whether scheduling addresses demand at all. Even with 7-OH and kratom scheduled, LaBelle told STAT, the underlying conditions leading people to seek the substances would remain, and scheduling is often "the only tool we have in our tool belt."

Nora Volkow, director of the National Institute on Drug Abuse, told STAT the rise in overdose reports involving kratom over the past five years was "not surprising" and that "it would minimize the harms if it is properly regulated." Volkow also expressed interest in what STAT described as "the potential that mitragynine may have as an addiction treatment and painkiller," a research interest she framed as hers rather than an established finding.

The state-regulation model

Leah Kaufman, vice president of state policy at Shatterproof, told STAT that Utah and West Virginia have the best-regulated kratom marketplaces in the country, and that the organization has helped about a half-dozen states develop policy. According to STAT, Utah requires a specialty tobacco retail license to sell kratom, keeps a public list of registered products, requires third-party laboratory testing, and amended its law earlier this year to prohibit the sale of anything other than "pure leaf kratom," including potent 7-OH products. Both states tax the products to fund enforcement, STAT reported. Kaufman said the Kratom Consumer Protection Act model, which STAT reported has been adopted in roughly two dozen states, offers weak protection. "The protections on that are so weak, they're not useful," she said.

Mac Haddow, the American Kratom Association's senior fellow on public policy, said kratom products can be regulated better. "Can kratom products be regulated better? Yes," Haddow told STAT. The association has said publicly that it supports the DEA's action against synthetic and concentrated 7-OH products and opposes bans that reach natural leaf kratom, a position it stated when it endorsed the DEA proposal in July.

STAT did not report a timeline for the DEA's final decision on the threshold rule, and the article does not specify the numerical threshold in the proposal.

Sources

  • Kratom and 7-OH should be regulated, experts agree. They're split on how STAT

    In July, the Drug Enforcement Agency proposed temporarily designating 7-OH above a certain threshold of potency as Schedule I. The agency has not yet finalized the law, but has moved three less common kratom-related synthetics into Schedule I without a threshold caveat. The extended public comment period ended on Sept. 10 with nearly 36,000 submissions.